TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:33
Barinthus Biotherapeutics plc. ( BRNS ) https://www.barinthusbio.com
1.06USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-70.90%
BRNS
SPY
32.66%
-89.60%
BRNS
SPY
108.59%
BRNS
0.00%
SPY
302.52%
BRNS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
43.76
-49.68
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.75
2.07
0.27
-123.99
0.00
1.03
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-62.66
100.00
-80.35
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-23.20
-23.47
0.00
Other Earnings and Cash Flow Stats:
Barinthus Biotherapeutics plc. ( BRNS ) Net Income TTM ($MM) is -57.98
Barinthus Biotherapeutics plc. ( BRNS ) Operating Income TTM ($MM) is -67.69
Barinthus Biotherapeutics plc. ( BRNS ) Owners' Earnings Annual ($MM) is 0.00
Barinthus Biotherapeutics plc. ( BRNS ) Current Price to Owners' Earnings ratio is 0.00
Barinthus Biotherapeutics plc. ( BRNS ) EBITDA TTM ($MM) is -61.88
Barinthus Biotherapeutics plc. ( BRNS ) EBITDA Margin is -80.35%
Capital Allocation:
Barinthus Biotherapeutics plc. ( BRNS ) has paid 0.00 dividends per share and bought back -0.885614 million shares in the past 12 months
Barinthus Biotherapeutics plc. ( BRNS ) has increased its debt by 12.669 million USD in the last 12 months
Capital Structure:
Barinthus Biotherapeutics plc. ( BRNS ) Interest-bearing Debt ($MM) as of last quarter is 12
Barinthus Biotherapeutics plc. ( BRNS ) Annual Working Capital Investments ($MM) are 14
Barinthus Biotherapeutics plc. ( BRNS ) Book Value ($MM) as of last quarter is 159
Barinthus Biotherapeutics plc. ( BRNS ) Debt/Capital as of last quarter is 7%
Other Balance Sheet Stats:
Barinthus Biotherapeutics plc. ( BRNS ) has 106 million in cash on hand as of last quarter
Barinthus Biotherapeutics plc. ( BRNS ) has 15 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Barinthus Biotherapeutics plc. ( BRNS ) has 39 common shares outstanding as of last quarter
Barinthus Biotherapeutics plc. ( BRNS ) has 0 million USD of preferred stock value
Academic Scores:
Barinthus Biotherapeutics plc. ( BRNS ) Altman Z-Score is -0.58 as of last quarter
Barinthus Biotherapeutics plc. ( BRNS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Barinthus Biotherapeutics plc. ( BRNS ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Barinthus Biotherapeutics plc. ( BRNS ) for the amount of $ on
9.40% of Barinthus Biotherapeutics plc. ( BRNS ) is held by insiders, and 46.22% is held by institutions
Barinthus Biotherapeutics plc. ( BRNS ) went public on 2021-04-30
Other Barinthus Biotherapeutics plc. ( BRNS ) financial metrics:
FCF:-58.09
Unlevered Free Cash Flow:0.00
EPS:-0.82
Operating Margin:-62.66
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-20.37
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Barinthus Biotherapeutics plc. ( BRNS ) :
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.